U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies

Cresco Labs

Market Cap: US$493.2m

Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany.

Curaleaf Holdings

Market Cap: US$3.6b

Engages in the retail and wholesale of cannabis products in the United States and internationally.

Pelthos Therapeutics

Market Cap: US$101.9m

A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.

High Tide

Market Cap: US$300.5m

Engages in the cannabis retail business in Canada, the United States, and internationally.

Trulieve Cannabis

Market Cap: US$2.1b

Operates as a cannabis retailer in the United States.

United Therapeutics

Market Cap: US$22.0b

Engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

CorMedix

Market Cap: US$645.4m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Elanco Animal Health

Market Cap: US$12.2b

An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.

Supernus Pharmaceuticals

Market Cap: US$2.6b

A biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

Prestige Consumer Healthcare

Market Cap: US$2.5b

Develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.

ANI Pharmaceuticals

Market Cap: US$1.6b

A biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.

Decibel Cannabis

Market Cap: US$72.1m

An integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.

Tarsus Pharmaceuticals

Market Cap: US$3.2b

A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.

Gyre Therapeutics

Market Cap: US$682.9m

A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.

Indivior Pharmaceuticals

Market Cap: US$4.3b

Engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.

Journey Medical

Market Cap: US$223.3m

A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.

Fennec Pharmaceuticals

Market Cap: US$399.8m

Operates as a commercial stage biopharmaceutical company in the United States.

ACADIA Pharmaceuticals

Market Cap: US$5.1b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

Forum Markets

Market Cap: US$79.6m

A financial technology company, develops a blockchain-based platform focused on the acquisition, structuring, and tokenization of real-world assets worldwide.

Viatris

Market Cap: US$19.0b

Operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.

ARS Pharmaceuticals

Market Cap: US$532.0m

A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.

Amphastar Pharmaceuticals

Market Cap: US$915.4m

A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.

UroGen Pharma

Market Cap: US$2.3b

A biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.

Protara Therapeutics

Market Cap: US$228.7m

A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.

Vanda Pharmaceuticals

Market Cap: US$322.3m

A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.

AVITA Medical

Market Cap: US$306.5m

Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.

Green Thumb Industries

Market Cap: US$2.3b

Manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States.

Verastem

Market Cap: US$621.3m

A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.

Astellas Pharma

Market Cap: US$4.3t

Engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally.

Grifols

Market Cap: US$6.0b

Engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.

Bayer

Market Cap: US$48.4b

Operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.

Madrigal Pharmaceuticals

Market Cap: US$11.8b

A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.

ADMA Biologics

Market Cap: US$2.1b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Zevra Therapeutics

Market Cap: US$691.8m

A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.

TG Therapeutics

Market Cap: US$7.9b

A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

Exelixis

Market Cap: US$13.5b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.